OTLK · Outlook Therapeutics, Inc.
$0.98
-0.05 (-5.02%)
At close · Aug 6
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$117.54M
Shares
120.86M
Outlook Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Outlook Therapeutics, Inc. (OTLK) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY24 · Q3
2024-08-14
Outlook Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
NORSE EIGHT clinical trial and US BLA
Commercial launch in Europe
Inventory and manufacturing
Diluted EPS
$-0.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-16
Outlook Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
Execution and milestone risk
US BLA path and NORSE EIGHT
European regulatory approval and launch
Diluted EPS
$-8.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-17
Outlook Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-05-13
Outlook Therapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-26
Outlook Therapeutics, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-20
Outlook Therapeutics, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-1.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-19
Outlook Therapeutics, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
16 filings
16 filers
Visit website
Investor relations